Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.50 |
| ▸ | USP7 | Q93009 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20926050 | 0.87 | NOS2 (0.54) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23450311 | 0.87 | MBOAT4 (0.56) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20926059 | 0.85 | MBOAT4 (0.48) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20925919 | 0.85 | MBOAT4 (0.47) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24352459 | 0.84 | NOS2 (0.56) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20925859 | 0.83 | MBOAT4 (0.48) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20853341 | 0.83 | NOS2 (0.50) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20925756 | 0.82 | MBOAT4 (0.51) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12968613 | 0.82 | MBOAT4 (0.70) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24511986 | 0.82 | NOS2 (0.56) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | REATA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190350941-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350941-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | NOS2 3518/4885KEAP1 694/4885CYP3A4 2497/4885 |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | HSD11B2, CYP21A2, HSD11B1 | NOS2 3518/4885KEAP1 694/4885CYP3A4 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.